Type 1 Diabetes Clinical Trial
— PARADIGMOfficial title:
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site
The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning kidney and/or liver transplants is safe, allows islet engraftment, and leads to insulin independence.
Status | Recruiting |
Enrollment | 8 |
Est. completion date | January 31, 2026 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female subjects age 18 or older. 2. Subjects who are able to provide written informed consent and to comply with study procedures. 3. Clinical history compatible with Type 1 diabetes (onset < 40 yrs old and insulin dependent for > 5 yrs at enrollment, c-peptide negative). 4. Recipients should have absent stimulated c-peptide (< 0.3 ng/mL) in response to a (Boost® 6 mL/kg BW to a maximum of 360 mL; another equivalent product), measured at 60 and 90 min after start of consumption. 5. Subjects who are > 6 months post-renal transplant or >6 months post-liver transplant who are taking appropriate calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic ± Prednisone = 10 mg/day). 6. Stable renal function as defined by a creatinine of no more than one third greater than the average creatinine determination performed in the 6 previous months prior to islet transplant, as well as absence of a rejection episode in the 6 months prior to islet transplant 7. Stable liver function tests as defined by: SGOT (AST), SGPT (ALT), alkaline phosphatase values < 1.5, or total bilirubin < 1.5 times normal upper limits at time of study entry, as well as absence of a rejection episode in the 6 months prior to islet transplant Exclusion Criteria: 1. Presence of donor specific anti-HLA antibodies detected by Luminex Single Antigen/specificity bead assay including weakly reactive antibodies that would not be detected by a flow cross match 2. Insulin requirement of >1.0 IU/kg/day 3. Weight more than 100 kg or body mass index (BMI) > 30 kg/m2. 4. Primary hyperparathyroidism OR secondary hyperparathyroidism 5. Untreated or unstable proliferative diabetic retinopathy. 6. Blood Pressure: SBP > 180 mmHg or DBP >100 mmHg despite treatment with antihypertensive agents. 7. Calculated GFR of = 40 mL/min/1.73 m2 using the subject's measured serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation, as well as presence of a rejection episode in the 6 months prior to islet transplant 8. Elevated liver function tests as defined by: SGOT (AST), SGPT (ALT), alkaline phosphatase values > 1.5, or total bilirubin >1.5 times normal upper limits at time of study entry, as well as presence of a rejection episode in the 6 months prior to islet transplant 9. Proteinuria (albumin/creatinine ratio or ACr > 300mg/g) of new onset since kidney transplantation. 10. For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo- Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. 11. Active infection including hepatitis B, hepatitis C, HIV, or TB. Quantiferon gold assay will be used to determine TB infection. 12. Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection within 1 year prior to study entry. 13. Any history of malignancy following receiving either the kidney or liver transplant, except for completely resected squamous or basal cell carcinoma of the skin 14. Known active alcohol or substance abuse. 15. Severe co-existing cardiac disease, characterized by any one of these conditions: 1. Recent MI (within past 6 months), 2. Evidence of ischemia on functional cardiac exam within the last year, 3. Left ventricular ejection fraction < 30%, 4. Valvular disease requiring replacement with prosthetic valve. 16. Active infections (except mild skin and nail fungal infections). 17. Active peptic ulcer disease or gastritis, symptomatic gallstones, or portal hypertension. 18. Use of any investigational agents within 4 weeks of enrollment. 19. Administration of live attenuated vaccine(s) within 2 months of enrollment. 20. Any medical condition that, in the opinion of the investigator, will interfere with safe study completion. 21. Positive screen for BK viremia at time of screening. 22. Untreated hyperlipidemia - TC > 200 mg/dL, TGC > 200 mg/dL, LDL > 130 mg/dL |
Country | Name | City | State |
---|---|---|---|
United States | University of California | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Peter Stock | California Institute for Regenerative Medicine (CIRM) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed. | Minimum of 1 year up to 2 years depending on transplant date | |
Primary | Incidence of post-transplant infections and malignancies | Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed. | Minimum of 1 year up to 2 years depending on transplant date | |
Primary | Incidence of de novo sensitization | Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed. | Minimum of 1 year up to 2 years depending on transplant date | |
Primary | Incidence of Insulin independence | Efficacy: Incidence of participants no longer using insulin | Minimum of 1 year up to 2 years depending on transplant date | |
Secondary | Glycemic control | Assessed by measuring HbA1c using high-performance liquid chromatography | Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2 | |
Secondary | Glycemic lability | Assessed with the Mean Amplitude of Glycemic Excursions (MAGE) test | Day 75, Day 180, Day 270, Year 1 | |
Secondary | Hypoglylcemic episodes: Clarke Survey Score | The Clarke survey will be used to assess the frequency and severity of hypoglycemic episodes | Day 75, Day 180, Day 270, Year 1 | |
Secondary | Hypoglylcemic episodes: Hypo Score | The HYPO score will be used to assess the frequency and severity of hypoglycemic episodes | Day 75, Day 180, Day 270, Year 1 | |
Secondary | Beta cell function as assessed by Mixed Meal Tolerance Test (MMTT) | Results from both MMTT and FSIGT will be used to assess beta cell function | Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2 | |
Secondary | Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT) | Results from both MMTT and FSIGT will be used to assess beta cell function | Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |